Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 3/20 | 0.50 |
| ▸ | RXRB | P28702 | 3/20 | 0.50 |
| ▸ | RXRG | P48443 | 3/20 | 0.50 |
| ▸ | TACR1 | P25103 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310946 | 0.89 | RXRA (0.51) | LMNAFFAR1FFAR4THRATHRB | |
| SCHEMBL7812479 | 0.89 | LMNA (0.51) | LMNAFFAR1FFAR4THRATHRB | |
| SCHEMBL30151169 | 0.88 | FFAR4 (0.48) | LMNAFFAR1FFAR4THRATHRB | |
| SCHEMBL30151149 | 0.88 | THRA (0.50) | LMNAFFAR1FFAR4THRATHRB | |
| SCHEMBL30151135 | 0.88 | THRA (0.47) | LMNAFFAR1FFAR4THRATHRB | |
| SCHEMBL28484226 | 0.86 | CES2 (0.48) | LMNATHRATHRBRXRARXRB | |
| SCHEMBL29172383 | 0.85 | MAPT (0.53) | LMNARXRARXRBRXRGTACR1 | |
| SCHEMBL14441580 | 0.84 | RXRA (0.56) | FFAR1FFAR4THRATHRBRXRA | |
| SCHEMBL18255658 | 0.84 | FFAR1 (0.50) | LMNAFFAR1FFAR4THRATHRB | |
| SCHEMBL3400672 | 0.82 | IDO1 (0.46) | LMNARXRARXRBRXRGTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | claimed |
| US-12415939-B2 | Nano-adhesive and surface primer compound and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-16 | — | — | US | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200181455-A1 | NANO-ADHESIVE AND SURFACE PRIMER COMPOUND AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-11 | — | — | US | disclosed |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-1318811-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6545023-B2 | For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2002030912-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1068244-A1 | METHOD FOR PRODUCING COPOLYMERS FROM FUNCTIONALISED OLEFINICALLY UNSATURATED MONOMERS AND NON-POLAR OLEFINICALLY UNSATURATED COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999047569-A1 | METHOD FOR PRODUCING COPOLYMERS FROM FUNCTIONALISED OLEFINICALLY UNSATURATED MONOMERS AND NON-POLAR OLEFINICALLY UNSATURATED COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | LMNA 4790/4885FFAR1 142/4885FFAR4 229/4885 |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | LMNA 3716/4885FFAR1 3121/4885FFAR4 3742/4885 |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | LMNA 868/4885FFAR1 713/4885FFAR4 697/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | LMNA 3716/4885FFAR1 3121/4885FFAR4 3742/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | LMNA 3718/4885FFAR1 3180/4885FFAR4 3852/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | LMNA 3716/4885FFAR1 3121/4885FFAR4 3742/4885 |
| US-12415939-B2 | Nano-adhesive and surface primer compound and use thereof | CDH1, EPCAM, ICAM1 | LMNA 3192/4885FFAR1 2341/4885FFAR4 2703/4885 |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | LMNA 868/4885FFAR1 713/4885FFAR4 697/4885 |
| US-20200181455-A1 | NANO-ADHESIVE AND SURFACE PRIMER COMPOUND AND USE THEREOF | CDH1, EPCAM, ICAM1 | LMNA 3192/4885FFAR1 2341/4885FFAR4 2703/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | LMNA 868/4885FFAR1 713/4885FFAR4 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.